Frontier Medicines
Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.
FMC-376 covalently targets GTP-bound and GDP-bound KRAS G12C, designed to overcome adaptive RTK feedback that limits first-generation G12C drugs. PROSPER phase 1/2 (NCT06244771) recruiting; primary completion estimated October 2027.
Pages like this
not linked directly; found by shared links- CompanyQuanta Therapeutics
Shares Covalent chemistry for the RAS mutations that still have no drug, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductElironrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers, Non-small-cell lung cancer.
- ProductZoldonrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- PersonFrank McCormick
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.